Clinic leaders proposed linking longevity tests to treatment and follow-up. Here is what the roundtable reported and what evidence is still needed.
On October 20, 2026, Longevity.Technology published an event report on the fourth Roundtable of Longevity Clinics and its push to connect testing with follow-up care. Eric Verdin, CEO of the Buck Institute for Research on Aging, chaired the discussion.
The central proposal was to replace isolated diagnostic snapshots with a recurring cycle: measure, treat, and measure again. According to Longevity.Technology, participants argued that longevity care should assess change over time rather than end with a biological-age score or offer interventions without appropriate assessment. For healthy-aging research, the important question raised by this proposal is whether treatment produces a meaningful benefit over time. The roundtable framed follow-up as a way to make clinics more accountable for what happens after their initial assessment.
Evidence setting: The report concerns care in humans. It is a professional event report, not a study conducted in vitro, in animal models, or in human participants.
The material records what clinic leaders and researchers advocated and described from their own practice. It should therefore be read as a discussion about how longevity medicine ought to work. AgeAmaze’s guide to how scientific claims progress toward medical use provides a broader framework for understanding that distinction.
Andrea B. Maier of the NUS Academy for Healthy Longevity told the roundtable that her team had spent five years developing standard operating procedures. The report says her team had moved away from relying on a single biological-age figure. Instead, Maier described reviewing organ systems and the genome first, with biological clocks as “the cherry on the cake.”
That ordering gives the proposal a different emphasis from a service built around delivering an age number. The clinical assessment comes first. The clock becomes one part of the discussion rather than the finding around which everything else must be arranged.
Verdin described a “diagnostic trap” in which a clinic performs extensive testing but leaves the patient without meaningful follow-up. He also warned that the word “longevity” covers a broad mix of services and products. In his account, that breadth can blur the distinction between science-based medicine and trend-driven offerings.
The proposed alternative connects the initial assessment to subsequent care. A result would lead to a considered response and then to an opportunity to reassess what happened. The editorial distinction is straightforward: collecting information and using information are different activities. The roundtable’s concern was that a clinic should be able to explain the connection between them.
One clinic described in the report returned results in stages over several weeks and followed patients as each stage arrived. It also described retesting at around eight weeks and again at one year to check whether interventions were working. These details illustrate how one provider organized the cycle from assessment through follow-up.
According to the event report, the Healthy Longevity Medicine Society (HLMS) and Longevity Clinics World had submitted a framework for publication. Its stated scope covered what clinics should measure and treat, along with how they should re-measure.
Those questions belong together. A proposed measurement needs an explanation of what it represents. A proposed intervention needs a reason for being connected to that result. Follow-up then needs a defined purpose so that another appointment is more than a repeat of the first.
This is an accountability model rather than simply a call to collect additional data. Its value as a proposal lies in making the connections explicit: what was assessed, what response followed, and what later assessment was intended to establish. Readers can use that sequence to understand a clinic’s reasoning without treating the existence of a monitoring programme as an endorsement of every service within it.
The report also described familiar areas of medicine such as sleep and muscle mass, alongside diet and screening. The discussion therefore concerned the organization and interpretation of care as well as biological-age testing. A useful reading keeps those parts of the proposal together rather than making the clock its central feature again.
The report described a public-hospital programme that had enrolled about 1,500 patients over three years. Around half reportedly used its companion app. Follow-up attendance could be affected by inconvenience or a lack of perceived need, as well as reluctance to know the results.
These observations bring the discussion back to how care is delivered. A recurring assessment cycle requires an opportunity to return and a reason the patient understands. In the programme described, the availability of an app and the existence of follow-up appointments were separate from whether people used them.
Another speaker attributed retention above 70% to a relationship-based approach. That observation reflects the roundtable’s interest in maintaining contact with patients after the initial assessment. It also raises an important interpretive question for readers: is a clinic describing continued participation or a health outcome? Those are different questions even when both matter to the service being discussed.
The report supports an account of a professional proposal and reported clinic experiences. Its main evidentiary limits are:
The practical response is to ask for the reasoning behind the proposed assessment. What is the test intended to measure? Can it be measured reliably in clinical practice? How would the result affect care?
For follow-up, the useful question is what outcome the clinic plans to track. The explanation should connect the initial finding to the proposed intervention and the later assessment. A reader can ask what would count as a meaningful change and how that interpretation would relate to health rather than to the score alone.
Clinic performance claims deserve similarly precise questions. If a provider cites retention or adherence, ask which outcome it is describing and how the figure was obtained. Keeping participation separate from health benefit makes the conversation clearer without dismissing the practical importance of continued care.
These questions support evaluation rather than prescribe a testing package. AgeAmaze’s discussion of matching intervention evidence to individual risk offers related context. Personal decisions about test results or treatment belong with a qualified clinician who can consider the individual’s health circumstances.
The next step is publication of the proposed framework followed by prospective studies testing whether its measures and follow-up decisions track meaningful health outcomes and improve care.
A clinic’s offer to repeat a biological-age test raises a concrete choice about the value of monitoring, which AgeAmaze helps readers assess through readable longevity reporting. For adults facing overstated biomarker and emerging-therapy claims, that context supports a clearer view of the evidence behind a proposed intervention and the uncertainty that remains.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
